Glucagon-like peptide 1 receptor agonists and venous thromboembolism in patients with obesity

Cho Han Chiang, M.D., M.M.Sc.
Mount Auburn Hospital/Harvard Medical School
Cambridge, MA, U.S.

Rushad Patell, M.B.B.S.
Beth Israel Deaconess Medical Center
Boston, MA, U.S.

Obesity is a known risk factor for venous thromboembolism (VTE). In this presentation, Cho Han Chiang investigates the effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on VTE risk in patients with obesity. A large, matched cohort analysis compared patients with obesity without prior VTE treated with GLP-1 RAs to those receiving other anti-obesity medications or bariatric surgery. GLP-1 RA treatment was associated with a significantly lower 12-month risk of VTE compared to other medications, particularly among patients without type 2 diabetes. No significant difference in VTE risk was observed between GLP-1 RA treatment and bariatric surgery.